Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

By J. Douillard, D. Cunningham, A. Roth, M. Navarro, R. James, P. Karásek, P. Jandík, T. Iveson, J. Carmichael, M. Alakl and 3 more. The Lancet, 2000

3,297 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/f74d75244c0000c6dbe7507b1fc73fc8f6179bc4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Cutsem
2. D. Elias
3. C. Fuchs
4. A. Falcone
5. F. Quénet
6. D. Arnold
7. G. Colucci
8. J. Marshall

Citations in the corpus

• Natural compounds for cancer treatment and prevention. (2009, background): “Themajor therapeutic indication for irinotecan is thefirst-line treatmentofmetastatic colorectal cancer patients in combinationwith 5-FU [78], and recently also with themonoclonal antibody bevacizumab [79].”
• Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial (2017, methodology): “Results are reported for (1) the primary 2-group comparison between cetuximab and bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and (3) the chemotherapy subgroups.”
• Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. (2005, methodology): “These results are somewhat lower than those reported by other authors with the same or similar regimens.(9,19,27,28) This difference may be a result of the patient characteristics selected in our trial, as commented on earlier.”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, neutral): “• FOLFOX note 1 [57, 58] +Bmab [54] • CapeOX note 2 + Bmab [59, 60] • FOLFIRI note 3 [61, 62] +Bmab [63, 64] • FOLFOX + Cmab/Pmab [65, 66] • FOLFIRI + Cmab/Pmab [67, 68] • FOLFOXIRI note 4 [69] • Infusional 5-FU + l-LV [70, 71] +Bmab [72, 73] • Cape [74, 75] + Bmab [76] • UFT + LV [77–79]”
• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007, methodology): “Results obtained in the FOLFIRI arm are in line with those reported in most other randomized studies.(2,8,26-29) With regard to FOLFOXIRI, results demonstrate that toxicities are moderately increased, mainly neurotoxicity and uncomplicated neutropenia, but this combination remains feasible and well ”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “FOLFIRI + BEV [190, 191] CAPIRI + BEV (see comment ⑤) [192] FOLFIRI + RAM [193] Fig.”
• 5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies (2008, background): “The overall response rate for advanced colorectal cancer of 5-FU alone is still only 10–15% [7], and the combination of 5-FU with other anti-tumor drugs has merely improved the response rates to 40–50% [8].”